Estimation of Variations in the Erythrocyte Sedimentation Rate in COVID-19 Recovered Patients

Manoj Aravindan a#, Palati Sinduja a*, R. Priyadharshini a† and V. Meghashree a†

a Department of Pathology, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai 77, Tamilnadu, India.

ABSTRACT

Background: A cluster of patients with pneumonia and severe acute respiratory syndrome developed in Wuhan, China in December 2019, and infection with a novel coronavirus virus called COVID-19 was later verified. Although fever and cough were the most common early signs and symptoms of COVID-19, extrapulmonary symptoms have also been reported. Many studies demonstrate that called COVID-19 swiftly progresses to acute respiratory distress syndrome and even multiple organ dysfunction.

Aim: The study aims to evaluate the erythrocyte sedimentation rate count in COVID-19 recovered individuals and compare it with healthy controls.

Materials & Methods: A cross-sectional pilot study in 5 healthy COVID-19 uninfected and 5 COVID-19 recovered individuals was conducted, the blood samples were collected and the erythrocyte sedimentation rate was calculated for each set of controls and samples. Statistical analysis was performed using SPSS software. An independent t-test was done to compare the results.

Results: The mean value of the control participants was found to be 8.08 ± 4.38 and the mean value of COVID-19 recovered patients was 20.60 ± 1.81. The difference in Erythrocyte Sedimentation Rate between the control and COVID-19 recovered patients was statistically significant (p < 0.05).

Authors’ contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: 10.9734/JPRI/2021/v33i59A34285

Received 10 October 2021
Accepted 15 December 2021
Published 16 December 2021
Sedimentation Rate (ESR) values between control individuals and COVID -19 recovered patients was statistically significant with p value of less than 0.005.

Conclusion: Within the limitations of the study, we conclude that the COVID -19 recovered patients has higher ESR values compared to the healthy uninfected individuals.

Keywords: COVID -19 recovered; blood sedimentation rate; humans; respiratory syndrome; extra-pulmonary syndrome.

1. INTRODUCTION

The pandemic global outbreak COVID -19 is a new human infecting beta coronavirus that is likely to be originated from the chrysanthemum bats [1]. The novel virus SARS- CoV- 2 is found to cause a type of pneumonia- associated condition termed Severe Acute Respiratory Syndrome (SARS) [2]. The virus appears to be spherical and has proteins called spikes protruding from their surface [3]. The pandemic outbreak COVID -19 spreads mainly by droplets produced as a result of coughing or sneezing of a COVID -19 infected person [4]. The spread of novel coronavirus occurs through direct close contact with COVID -19 patients within one meter of the infected person and the rate of spread is enhanced especially if they do not cover their face when coughing or sneezing [5]. The novel virus also spreads by the droplets surviving on surfaces and clothes for many days [6]. Therefore, touching any such infected surface or cloth and then touching one’s mouth, nose or eyes can transmit the disease [7]. Chloroquine, an ancient drug used for the treatment of malaria, and its derivative, hydroxychloroquine, have demonstrated been reported as effective immunomodulatory therapies in the treatment of the cytokine storm associated COVID -19 SARS [8].

The Erythrocyte Sedimentation Rate (ESR) is assay that can indirectly measure the degree of inflammation that is present in the body [9]. ESR measures the rate of sedimentation of erythrocytes in a sample of blood. ESR can also be influenced by anemia, low serum albumin, macrocytosis, age, and ethnicity of the patient. Increased red cell distribution width (RDW) is correlated with elevated ESR, C-reactive protein (CRP), and disease activity in SLE patients. COVID -19 has been demonstrated in other researches to swiftly progress to acute respiratory distress syndrome and even multiple organ dysfunction, the clue to which can be obtained by the levels of ESR in blood. Because most research has focused on changes in the respiratory system, our knowledge of COVID -19 is still limited and the characteristics of other organ involvement and prognosis in COVID -19 patients are unknown.

Erythrocyte sedimentation rate (ESR) increased during COVID -19 recovery. The high level of ESR is sustained for an extended time even after the patient recovers from COVID -19 which results in the risk of a tumor, tuberculosis, rheumatic diseases, and anemia. Although the increased ESR cannot be explained without any existing evidence, it may links with the abnormal pathologic changes in some of COVID -19 recovered patients and show the negative prognosis which provides the clue to reduce the mechanism of illness progressing in COVID -19 recovered patients. Our team has extensive knowledge and research experience that has translate into high quality publications [10-29]. This study aims to evaluate the erythrocyte sedimentation rate count in COVID -19 recovered individuals and compare it with healthy controls.

2. MATERIALS AND METHOD

The present cross-sectional study was conducted in Saveetha Dental College & Hospitals in august 2021 and involved normal uninfected healthy individuals and patients affected with COVID -19 and recovered three months ago.

2.1 Demographic Data

The study included a total of n=10 participants who were divided into two groups. The mean age of the participants was 18-21 years. Among the participants 6 were males and 4 were females. The group I consist of control healthy individuals, group II consisted of COVID -19 recovered patients who recovered uneventfully three months before the initiation of the study.

2.2 Patients Selection and Recruitment

The samples were recruited from the COVID -19 recovered patients. Clinical history was taken
from COVID-19 recovered patients. It was also ensured that patients with systemic comorbidities or terminally ill patients were not included in the study. All the patients included in the study belonged to the same ethnic group of Tamil Nadu. Informed consent was obtained from the patients for inclusion into the study and it was also ensured that the patient's anonymity was maintained. All the patients completed a questionnaire covering medical, residential, and occupational history.

2.3 Statistical Analysis

The sampling method followed in this comparative study is random sampling based on the outpatients visiting the college. The mean values of each parameter were tabulated along with the significant values and plotted in the form of bar graphs using SPSS. Independent t-test analysis was used to compare the results that were obtained.

3. RESULTS

3.1 Correlation of Erythrocyte Sedimentation Rate and the Groups

The mean value of the ESR of control participants was found to be 8.08 ± 4.38 (mm/h) and the mean value for the COVID-19 recovered patients was found to be 19.8 ± 1.81 (mm/h). The ESR count difference between control and COVID-19 recovered patients was observed with a p-value of less than 0.005 which is considered to be statistically significant.

Table 1. Statistical ESR (mm/h) parameters: mean, Standard Deviation and Standard Error

| Group            | Mean | Std. Deviation | Std. Error | Sig. |
|------------------|------|----------------|------------|------|
| Control          | 8.8  | 4.38           | 1.95       | <0.005|
| COVID-19 Recovered | 19.8 | 1.81           | 0.81       |      |

Significance at the levels of p<0.005

Fig. 1. Bar graph depicts the association between the group of patients and Mean ESR Value. The X-axis represents the group of patients included in the study and Y-axis represents the mean ESR value. The blue color denotes the control group and the Green color denotes the COVID-19 recovered patients. The COVID-19 recovered group of patients has shown an increase in the ESR value when compared to the control group, with a p-value <0.005, which is considered to be statistically significant. The above Error bar graph shows a 95% CI value.
4. DISCUSSION

In our study, we were able to find that there is a significant rise in the level of the ESR value in the COVID-19 recovered patients even after three months of uneventful recovery of these patients when compared to the control group. The individuals who were considered as samples for the recovered group were all home quarantined and did not have any serious ailments during the entire duration of the infection. Despite of a full recovery, we were able to observe that the ESR values of these patients were higher when compared to the healthy control group who were age and sex-matched to give a more comparative result.

Klinck et al. discovered that the ESR began to rapidly increase about 2 weeks after COVID-19 infection [30] indicating that even though the signs of fever and dry cough faded and the alteration in chest CT symptoms improved, the ESR remained elevated for a long period [31]. Brouillard et al mentioned in his study that increased level of ESR cannot be explained by all existing data, it may be associated with abnormal pathologic change in some COVID-19 patients with poor outcomes, which gives a good idea to decode the mechanism of COVID-19 illness severity and prognosis [32]. A previous study by Sheng et al. found that there is an aberrant lymphopenia presented after COVID-19 and returned to normal level after recovery from a viral infection, which is consistent with typical characteristics of viral infection [33]. Hess CT et al. found that the COVID-19 such as pneumonia could be associated with bacterial infection as the illness progressed, as the research indicates that inflammatory markers such as leukocyte and neutrophil counts, IL–6, and CRP levels were elevated [34].

The present study is in concordance with a study by Klinck et al who quoted that ESR dramatically increase around two weeks after COVID-19 infection, and the high level of ESR persisted for a long period despite the absence of fever and dry cough [30]. In support of these findings, the ESR rate in the present study is found to be increased in the COVID-19 recovered population despite of recovering from the infection for three months.

The present study possesses limitations such as a paucity of subjects. Further studies with large samples, and a better focus on details concerned with variables like age, gender should be done to significantly demonstrate the greater ESR values in COVID-19 recovered patients than in controlled individuals.

5. CONCLUSION

Within the limitations of the study, we conclude that the Erythrocytes sedimentation rate of the COVID-19 recovered patients was found to be increased when compared to the normal control group providing insight into the illness progression and long-term impact of COVID-19 on patients. These individuals did not have any serious ailments during the entire duration of the infection and despite of a full recovery, we were able to observe that the ESR values of these patients were high and abnormal when compared to the healthy age and sex matched control group.

CONSENT

As per international standard or university standard, patients’ written consent has been collected and preserved by the author(s).

ETHICAL APPROVAL

The study and sample collection were approved by the Institutional ethical committee with an approval number of IHEC/SDC/UG-1900/21/211.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Junot H, Méloni C, Bleibtreu A, Robert A. Impact de la pandémie COVID-19 sur les consommations hospitalières en antibiotiques, étude monocentrique d’un ESR métropolitain, Médecine et Maladies Infectieuses. 2020;50:S94. Available: http://dx.doi.org/10.1016/j.medmal.2020.06.190
2. Arestov IM, Anisochkin AA, Yudakov OI, Sukhareva EA. How informative are the leukocyte formula and ESR for COVID-19 patients’ monitoring? ТЕНДЕНЦИИ РАЗВИТИЯ НАУКИ И ОБРАЗОВАНИЯ. 2021;73:81–5. Available: http://dx.doi.org/10.18411/1lj-05-2021-65
3. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J Med Virol. 2020;92(4):441–7.

4. Rello J, Tejada S, Userovici C, Arvaniti K, Pugin J, Waterer G. Coronavirus Disease 2019 (COVID-19): A critical care perspective beyond China. Anaesthesia Critical Care & Pain Medicine. 2020;39:167–9. Available: http://dx.doi.org/10.1016/j.accpm.2020.03.001

5. Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020;69:1143–4. Available: http://dx.doi.org/10.1136/gutjnl-2020-320891

6. Ng O-T, Marimuthu K, Chia P-Y, Koh V, Chiew CJ, De Wang L, et al. SARS-CoV-2 Infection among Travelers Returning from Wuhan, China New Journal of Medicine. 2020;382:1476–8. Available: http://dx.doi.org/10.1056/nejmc2003100

7. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome, The Lancet Respiratory Medicine. 2020;8:420–2. Available: http://dx.doi.org/10.1016/s2213-2600(20)30076-x

8. Lu C-W, Liu X-F, Jia Z-F. 2019-nCoV transmission through the ocular surface must not be ignored. The Lancet. 2020;395:e39. Available: http://dx.doi.org/10.1016/s0140-6736(20)30313-5

9. Stojan G, Fang H, Magder L, Petri M. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity, Lupus. 2013;22:827–34. Available: http://dx.doi.org/10.1177/0961203313492578

10. Anitha R, Paramasivam A, Priyadarsini JV, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res. 2020;10(8):2546–54.

11. Jayaseelan VP, Paramasivam A. Emerging role of NET inhibitors in cardiovascular diseases. Hypertens Res. 2020;43(12):1459–61.

12. Sivakumar S, Smiline Girija AS, Vijayashree Priyadarsini J. Evaluation of the inhibitory effect of caffeic acid and gallic acid on tetR and tetM efflux pumps mediating tetracycline resistance in Streptococcus sp., using computational approach. Journal of King Saud University - Science. 2020;32(1):904–9.

13. Smiline Girija AS. Delineating the Immuno-Dominant Antigenic Vaccine Peptides Against gacS-Sensor Kinase in Acinetobacter baumannii: An in silico Investigational Approach. Front Microbiol. 2020;11:2078.

14. Iswarya Jaisankar A, Smiline Girija AS, Gunasekaran S, Vijayashree Priyadarsini J. Molecular characterisation of csgA gene among ESBL strains of A. baumannii and targeting with essential oil compounds from Azadirachta indica. Journal of King Saud University - Science. 2020;32(8):3380–7.

15. Girija ASS. Fox3+ CD25+ CD4+ T-regulatory cells may transform the nCoV’s final destiny to CNS! J Med Virol [Internet]. 2020 Sep 3; Available from: http://dx.doi.org/10.1002/jmv.26482

16. Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. Environ Sci Pollut Res Int. 2021; 28(21):27162–73.

17. Arumugam P, George R, Jayaseelan VP. Aberrations of m6A regulators are associated with tumorigenesis and metastasis in head and neck squamous cell carcinoma. Arch Oral Biol. 2021 Feb;122:105030.

18. Kumar SP, Girija ASS, Priyadarsini JV. Targeting NM23-H1-mediated inhibition of tumour metastasis in viral hepatitis with bioactive compounds from Ganoderma lucidum: A computational study. Pharmaceutical-sciences. 2020;82(2). Available: https://www.ipjsonline.com/article s/targeting-nm23h1mediated-inhibition-of-tumour-metastasis-in-viral-hepatitis-with bioactive-compounds-from-ganoderma lucidum-a-comp-3883.html

19. Girija SA, Priyadarsini JV, Paramasivam A. Prevalence of carbapenem-hydrolyzing OXA-type β-lactamases among Acinetobacter baumannii in patients with severe urinary tract infection. Acta Microbiol Immunol Hung. 2019;67(1):49–55.

20. Priyadarsini JV, Paramasivam A. RNA editors: key regulators of viral response in cancer patients. Epigenomics. 2021;13(3):165–7.
21. Mathivadani V, Smiline AS, Priyadharsini JV. Targeting Epstein-Barr virus nuclear antigen 1 (EBNA-1) with Murraya koengii bio-compounds: An in-silico approach. Acta Virol. 2020;64(1):93–9.

22. Girija As S, Priyadharsini JVAP. Prevalence of Acb and non-Acb complex in elderly population with urinary tract infection (UTI). Acta Clin Belg. 2021;76(2):106–12.

23. Anchana SR, Girija SAS, Gunasekaran S, Priyadharsini VJ. Detection of csgA gene in carbapenem-resistant Acinetobacter baumannii strains and targeting with Ocimum sanctum biocompounds. Iran J Basic Med Sci. 2021;24(5):690–8.

24. Girija ASS, Shoba G, Priyadharsini JV. Accessing the T-Cell and B-Cell Immuno-Dominant Peptides from A.baumannii Biofilm Associated Protein (bap) as Vaccine Candidates: A Computational Approach. Int J Pept Res Ther. 2021;27(1):37–45.

25. Arvind PTR, Jain RK. Skeletally anchored forus fatigue resistant device for correction of Class II malocclusions-A systematic review and meta-analysis. Orthod Craniofac Res. 2021;24(1):62–61.

26. Venugopal A, Vaid N, Bowman SJ. Outstanding, yet redundant? After all, you may be another Choluteca Bridge! Semin Orthod. 2021;27(1):53–6.

27. Ramadurai N, Gurunathan D, Samuel AV, Subramanian E, Rodrigues SJL. Effectiveness of 2% Articaine as an anesthetic agent in children: randomized controlled trial. Clin Oral Investig. 2019;23(9):3543–50.

28. Varghese SS, Ramesh A, Veeraiyan DN. Blended Module-Based Teaching in Biostatistics and Research Methodology: A Retrospective Study with Postgraduate Dental Students. J Dent Educ. 2019;83(4):445–50.

29. Mathew MG, Samuel SR, Soni AJ, Roopa KB. Evaluation of adhesion of Streptococcus mutans, plaque accumulation on zirconia and stainless steel crowns, and surrounding gingival inflammation in primary molars: randomized controlled trial. Clinical Oral Investigations. 2020;24:3275–80. Available:http://dx.doi.org/10.1007/s00784-020-03204-9

30. Klinck GH. The Effect of the Injection of Trypan Blue on the Sedimentation Rate of Erythrocytes in Inflammation [Internet]. The American Journal of the Medical Sciences. 1931;181:743. Available:http://dx.doi.org/10.1097/0000041931050000-00064

31. Hardison CS. The sedimentation rate. Erythrocyte sedimentation rate; blood sedimentation rate JAMA: The Journal of the American Medical Association. 1968;204:257–257. Available:http://dx.doi.org/10.1001/jama.204.3.257

32. Brouillard M, Reade R, Boulanger E, Cardon G, Dracon M, Dequiedt P, et al. Erythrocyte sedimentation rate, an underestimated tool in chronic renal failure. Nephrology Dialysis Transplantation. 1996;11:2244–7. Available:http://dx.doi.org/10.1093/oxfordjournals.ndt.a027143

33. Pu SL, Zhang X-Y, Liu D-S, Ye B-N, Li J-Q. Unexplained elevation of erythrocyte sedimentation rate in a patient recovering from COVID-19: A case report [Internet]. Vol. 9, World Journal of Clinical Cases. 2021;1394–401. Available:http://dx.doi.org/10.12998/wjcc.v9i6.1394

34. Hess CT. Monitoring Laboratory Values [Internet]. Vol. 22, Advances in Skin & Wound Care. 2009;96. Available:http://dx.doi.org/10.1097/01.asw.0000345287.28403.76

© 2021 Aravindan et al.; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here:
https://www.sdiarticle5.com/review-history/77144